Jinhyuk Chung

xylonix.io

Xylonix.io is an innovative cancer immunotherapy development company for novel anticancer therapies that help realize the curative potential of cancer immunotherapy. Today's cancer immunotherapies demonstrated cure potentials across general cancer types, but the promblems of unpredictable treatment responses and low patient response rates remain. Our proprietary first-in-class Onco-Parthanatos platform technology kills and turns cancer into its own inflammatory antigens for initiating effective anti-cancer immune responses, for solving the reliability problems with today's cancer immunotherapies.